OR WAIT null SECS
© 2023 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
In this week's news roundup from Rheumatology Network, we feature a one-on-one interview with Dr. Michael Lewiecki.
November 13, 2022
Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.
“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."
November 12, 2022
Gout, if left untreated, can lead to flares that can increase the likelihood of depression and anxiety.
Wipfler emphasized that most of the delays have been associated with pharmacies needing to confirm the purpose of the prescription with the provider.
November 11, 2022
“We imagine that the rate of problems [accessing methotrexate] is going to be much higher in higher-risk populations," Wipfler explained.
October 24, 2022
John Cush, MD, discusses his CCR West presentation “Rheumatology Year in Review: 2022.”
October 21, 2022
John Cush, MD, discusses his presentation “Rheumatoid Arthritis: How Early is Too Early to Diagnose and Treat?”
October 06, 2022
Drs. Anne E. Winkler and Kristi V. Mizelle share practice pearls to optimize the management of patients of patients diagnosed with lupus.
Experts in rheumatology provide an overview of novel treatment options currently under investigation for the treatment of systemic lupus erythematosus and lupus nephritis.
Kristi V. Mizelle, MD, MPH, FACR comments on long term efficacy data on the use of biologics in lupus, with a focus on preventing organ damage.